U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07164794) titled 'Memantine Hydrochloride in Prostate Cancer Patients' on Aug. 13.
Brief Summary: The goal of this clinical trial is to learn if long-term use of memantine hydrochloride can treat, prevent, or correct castration resistance and drug resistance in advanced prostate cancer. The study will enroll male patients aged 18 and older diagnosed with metastatic castration-resistant prostate cancer (mCRPC) who have previously failed first or second-line treatments. The main questions it aims to answer are:
What is the progression-free survival (PFS) in patients treated with memantine hydrochloride? What is the disease control rate (DCR) and what...